A retrospective study of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation receiving anticoagulants
Latest Information Update: 02 Jan 2020
Price :
$35 *
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
- Indications Thromboembolism
- Focus Therapeutic Use
- 02 Jan 2020 New trial record